FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to the constant region of IgG2, in which His at position 147, Arg at position 234 and Gln at position 298 in the amino acid sequence SEQ ID NO: 2 are replaced by Gln, Gln and Glu, respectively, to the constant region of IgG2, in which Cys at position 14, Arg at position 16, Cys at position 102, Glu at position 20, Ser at position 21, His at position 147, Arg at position 234 and Gln at position 298 in the amino acid sequence SEQ ID NO: 2 are replaced by Ser, Lys, Ser, Gly, Gly, Gln, Gln and Glu, respectively, and also to the constant region of IgG2, in which Cys at position 14, Arg at position 16, Cys at position 102, Glu at position 20, Ser at position 21, His at position 147, Arg at position 234, Gln at position 298 and Asn at position 313 in the amino acid sequence SEQ ID NO: 2 are replaced by Ser, Lys, Ser, Gly, Gly, Gln, Gln, Glu and Ala, respectively.
EFFECT: invention is effective for improving the pharmacokinetics of the antibody.
3 cl, 24 dwg, 5 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED ANTIBODY CONSTANT REGION | 2021 |
|
RU2797273C2 |
METHOD OF PRODUCING VARIANTS OF FCYRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2820161C1 |
VERSIONS OF FCΓRIIB-SPECIFIC FC-REGION | 2013 |
|
RU2729831C2 |
METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING OF TWO OR MORE ANTIGEN MOLECULES | 2014 |
|
RU2756029C2 |
Fc-REGION OPTION | 2014 |
|
RU2757124C2 |
SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
Authors
Dates
2025-04-07—Published
2023-05-26—Filed